Methadone Witnessed Doses

During the provision of opioid dependence treatment, pharmacists will be required to witness patients taking their doses. While many patients have witnessed doses daily, others will have witnessed doses on select days and are then permitted to take home the remainder of their doses for the week. Witnessed dose days are most often determined by the patient and prescriber and remain consistent during their treatment. However, circumstances may arise where a patient may be required to change their scheduled observe day as a result of employment, travel or illness, as an example. The pharmacist may, using professional judgement and in discussion with the patient, make a change to the day the patient has their witnessed dose. It is important that any change in scheduled witness dose days be communicated to the prescriber as soon as possible as this information will inform random audits completed by the prescriber. The Opioid Dependence Treatment-Prescriber Fax form, under additional details, may be used to communicate changes to witness dose days. Regardless of which day a patient has witnessed doses, it is considered best practice that patients have at least one witnessed dose every 7 days.

College Seeking Feedback on Proposed Naloxone Policy

As of June 24, 2016 naloxone moved changed from a Schedule I to a Schedule II drug when indicated for emergency use for opioid overdose outside hospital settings. This means that the public may purchase naloxone without a prescription through a retail pharmacy. In light of this schedule change as well as the uniqueness of naloxone as a Schedule II drug, the PEI College of Pharmacists has drafted a policy that will provide members with information on education and training opportunities, counselling points, and additional materials needed when dispensing naloxone. The PEI College of Pharmacists has made the draft policy available below and would appreciate any comments on the policy by August 31, 2016. Your input is greatly appreciated. Please send comments to Registrar@pepharmacists.ca

Draft Policy for Pharmacy Professionals
Dispensing or Selling Naloxone.